488 related articles for article (PubMed ID: 10949579)
1. The plasminogen activation system in tumor growth, invasion, and metastasis.
Andreasen PA; Egelund R; Petersen HH
Cell Mol Life Sci; 2000 Jan; 57(1):25-40. PubMed ID: 10949579
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis: the key to new pathogenetic mechanisms.
Zorio E; Gilabert-Estellés J; España F; Ramón LA; Cosín R; Estellés A
Curr Med Chem; 2008; 15(9):923-9. PubMed ID: 18473800
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
5. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy.
Sidenius N; Blasi F
Cancer Metastasis Rev; 2003; 22(2-3):205-22. PubMed ID: 12784997
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
[TBL] [Abstract][Full Text] [Related]
7. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
8. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
10. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
12. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
14. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
[TBL] [Abstract][Full Text] [Related]
15. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
16. Plasmin/plasminogen system in colorectal cancer.
Berger DH
World J Surg; 2002 Jul; 26(7):767-71. PubMed ID: 11965442
[TBL] [Abstract][Full Text] [Related]
17. Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin.
De Lorenzi V; Sarra Ferraris GM; Madsen JB; Lupia M; Andreasen PA; Sidenius N
EMBO Rep; 2016 Jul; 17(7):982-98. PubMed ID: 27189837
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
19. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.
Testa JE; Quigley JP
Cancer Metastasis Rev; 1990 Dec; 9(4):353-67. PubMed ID: 2129023
[TBL] [Abstract][Full Text] [Related]
20. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Meissauer A; Kramer MD; Schirrmacher V; Brunner G
Exp Cell Res; 1992 Apr; 199(2):179-90. PubMed ID: 1531956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
